Can Immunotherapy Cure Stage 4 Cancer? What a Durable Response Means

There is a particular kind of scan report that oncologists used to see almost never, and now see occasionally: a patient with cancer that had spread to the liver and lungs, treated years ago, and the images are quiet. No new spots. The old ones shrunk to scar tissue or vanished. The physician reading it will feel real joy, and will also, very carefully, not say the word “cured.”

That caution frustrates families. If the cancer has been gone for five years, what else would you call it? The answer sits in the difference between what a treatment has already proven and what we hope it will prove given more time. Immunotherapy has changed the arithmetic of advanced cancer, but it has done so unevenly, and the honest version of the story includes the people it did not help.

This article walks through what the evidence actually shows, what a “durable response” means in practice, and why that phrase is doing a lot of quiet work.

What does stage 4 cancer actually mean, and why is "cure" such a loaded word?

Stage 4 describes location, not a countdown. It means cancer cells have traveled from where they began and established themselves somewhere else in the body: a lung tumor now growing in bone, or a skin melanoma with deposits in the liver. Clinicians also call this metastatic or distant-stage disease. It says nothing on its own about how fast the cancer is moving or how a person feels.

For most of medical history, stage 4 also meant treatment goals shifted. Surgery could remove one tumor but not scattered cells. Chemotherapy could shrink disease and buy time, sometimes a great deal of time, but the cancer usually found a way back. Doctors spoke of control rather than cure.

The word “cure” carries a specific meaning in oncology: the disease is gone and will not return during a person’s lifetime. You can only confirm it in hindsight, which is why physicians lean on proxies such as five-year survival or, increasingly, ten-year survival. Even then, some cancers relapse after long quiet stretches, so the profession treats the word with respect.

Immunotherapy has muddied this picture in a hopeful way. Some patients with metastatic disease now go years without evidence of cancer, off treatment, living ordinary lives. Whether those people are cured or in a very long remission is, at this point, a question of how long we have been watching. The National Cancer Institute’s own patient materials describe immunotherapy as a treatment that helps the immune system fight cancer, and stop short of promising permanence for good reason.

How does immunotherapy work against cancer?

Your immune system already destroys abnormal cells every day. T cells patrol tissues, recognize proteins that look wrong, and kill the cells carrying them. Cancers survive partly by hiding: they mutate to look ordinary, they recruit suppressive cells around themselves, and they exploit the body’s own “brakes” designed to prevent autoimmune attacks.

The most widely used immunotherapies today are checkpoint inhibitors. A checkpoint is a protein handshake between a T cell and another cell that tells the T cell to stand down. Tumors learn to offer that handshake constantly. Checkpoint inhibitors are antibodies that block the handshake, releasing T cells that were already primed against the cancer but held in check. The National Cancer Institute describes several such checkpoints, including one pathway that acts inside lymph nodes early in an immune response and another that acts directly at the tumor.

Other approaches take a different route. CAR T-cell therapy removes a patient’s own T cells, engineers them in a laboratory to recognize a marker on the cancer, multiplies them, and returns them. Cancer vaccines and certain immune-stimulating proteins aim to teach or amplify a response rather than unblock one.

The key idea unites all of them: the drug is not the weapon. The immune system is. That single fact explains almost everything unusual about immunotherapy, from how long it takes to work, to why responses can outlast treatment, to why side effects can appear in organs the cancer never touched.

Can immunotherapy cure stage 4 cancer? What the evidence really shows

Here is the fairest summary the data allow: immunotherapy has produced long-term survival in a subset of patients with metastatic disease that earlier treatments almost never achieved, and it has done nothing meaningful for many others.

Melanoma is where the story is best documented. A 2018 review in the journal Science by immunologists Ribas and Wolchok summarized long-term follow-up from early checkpoint trials: roughly one in five patients with metastatic melanoma treated with the first approved checkpoint inhibitor were still alive many years later, with survival curves flattening rather than sliding toward zero. Before these drugs, median survival for metastatic melanoma was measured in months, not years.

Population statistics tell a complementary story. The National Cancer Institute’s SEER program reports that five-year relative survival for melanoma that has spread to distant sites now sits around 35 percent across all patients and all treatments combined. That number would have seemed implausible two decades ago, and immunotherapy is a major reason it moved.

Still, notice what those figures do not say. A flattening curve at one in five means four in five did not get that outcome. A 35 percent five-year figure means most people with distant melanoma still die of it. And melanoma is the best case. For many other metastatic cancers, checkpoint inhibitors help a smaller fraction, extend life by months rather than years, or have not proven useful at all. “Can it cure stage 4 cancer” has a truthful answer: sometimes, for some cancers, for some people, and we are still counting.

What is a durable response, and why do oncologists prefer that phrase?

A response, in trial language, means a tumor shrank by a defined amount on imaging. A complete response means no measurable cancer remains. A durable response means that shrinkage held for a long time, often defined as a year or more, and in the most encouraging cases for many years after treatment stopped.

The word choice is deliberate. “Durable” describes what has been observed. “Cure” predicts what will happen next. Oncologists have been burned by prediction before; some cancers relapse after a decade of silence. So they report what they can measure and let time do the rest.

What makes immunotherapy’s durable responses distinctive is the shape of the survival curve. Chemotherapy curves typically descend steadily: benefit, then relapse, then decline. Checkpoint inhibitor curves in melanoma, as the Ribas and Wolchok review describes, often drop initially and then flatten into a plateau. The people on that plateau are not dying of their cancer at the rate the disease would predict. The best explanation is immunological memory: T cells that learned to recognize the tumor keep doing their job long after the last infusion.

A plateau is not proof of cure, but it is the closest thing to it that stage 4 oncology has ever routinely produced. When your oncologist uses the phrase “durable response,” they are not hedging to protect themselves. They are describing a real and unusual thing with the precision it deserves.

Why do some people respond to immunotherapy and others do not?

Two patients with the same cancer, the same stage, and the same treatment can have opposite outcomes. The reasons are partly understood and partly still being worked out.

Mutations matter. Cancers with many DNA changes produce many abnormal proteins, giving T cells more targets to recognize. Melanoma and smoking-related lung cancers carry heavy mutation loads, which is one reason they respond more often. Cancers driven by a few precise mutations, with otherwise tidy DNA, can be nearly invisible to the immune system.

Some tumors carry a specific DNA-repair defect called mismatch repair deficiency, which floods the cancer with mutations. The National Cancer Institute notes that this feature, wherever the cancer started, marks tumors that may respond to checkpoint therapy. It is one of the few biomarkers used across cancer types.

Then there is the neighborhood. A tumor already infiltrated by immune cells, sometimes called “hot,” is primed for checkpoint release. A “cold” tumor with few T cells nearby has nothing to unleash. Levels of the checkpoint protein on tumor cells, the diversity of a patient’s gut bacteria, prior treatments, and overall immune health all appear to influence outcomes, though none predicts reliably on its own.

What this means for a patient is practical: before recommending immunotherapy, oncology teams often test the tumor for these markers. The results shape the odds, not the certainty. Someone with a favorable profile can still fail to respond, and occasionally a person with poor markers surprises everyone.

Which cancers respond best to immunotherapy?

Response varies enormously by cancer type, and any table compresses a complicated literature. Treat the one below as a map of where the evidence is strongest, not a personal forecast. Categories reflect how consistently checkpoint inhibitors have shown benefit in metastatic disease, drawing on the National Cancer Institute’s descriptions of approved uses and the Ribas and Wolchok review.

Cancer type (metastatic)	Checkpoint inhibitor evidence	Common reasons
Melanoma	Strongest; long-term plateau documented	High mutation load, immune-visible
Non-small cell lung cancer	Established benefit for many patients	Mutation load, checkpoint protein levels
Kidney cancer	Established benefit	Immune-infiltrated tumors
Bladder cancer	Established for a subset	Variable markers
Mismatch-repair-deficient tumors (any site)	Established, marker-driven	Extremely high mutation load
Certain lymphomas	Established	Checkpoint protein overexpression
Pancreatic, most prostate, most breast, most colorectal	Limited or no benefit so far	Few mutations, immune-cold environment

Two caveats. First, “limited benefit” is a statement about today’s checkpoint inhibitors, not a verdict on immunotherapy as a field; trials in cold tumors are exploring ways to warm them. Second, the row a cancer sits in describes populations. Within lung cancer, for instance, patients whose tumors carry high checkpoint protein levels fare quite differently from those with none. Ask your team where your specific tumor falls.

How long does immunotherapy take to work?

Slower than chemotherapy, usually, and for a logical reason. Chemotherapy poisons dividing cells directly, so shrinkage can appear within a cycle or two. Immunotherapy has to recruit, expand, and deploy an army. The National Cancer Institute’s patient guidance notes that immunotherapy can take longer to show an effect than other treatments, and that scans may not reflect what is happening for some time.

In practice, most oncology teams schedule the first imaging check a couple of months into treatment, then reassess at intervals. Some patients feel better before scans change: less pain, more energy, a cough easing. Others feel nothing different and are then surprised by a good scan. Symptoms and images do not always move together.

Early scans also require careful reading, which the next section explains. A tumor that looks slightly bigger at the first check is not necessarily growing.

A separate question is how long benefit lasts once it appears. Here immunotherapy’s slowness becomes an asset. Because the effect runs through the immune system rather than through drug levels in the blood, responses can persist for months or years after treatment ends. That is the basis of the durable response discussed earlier, and it is why some trial protocols were designed to stop treatment after a fixed period and simply watch.

The frustrating truth for patients is that the waiting is real. Two or three months of uncertainty, with side effects and no scan to reassure you, is hard. Telling your team how you are coping, not just what your body is doing, is part of the treatment.

What is pseudoprogression, and why can a tumor look bigger before it shrinks?

Imagine a fortress under siege. From a satellite, the footprint grows as the attacking army surrounds the walls. Nothing about the fortress has expanded; the picture just includes more people. Pseudoprogression is that image applied to a tumor.

When checkpoint inhibitors work, immune cells pour into the tumor. On a CT scan, that influx can make the mass measure larger, or make new small spots appear where immune cells have gathered around previously invisible deposits. A radiologist reading with chemotherapy rules would call it progression. Under immunotherapy, it may be the opposite.

Pseudoprogression is uncommon, and it is not the default explanation for growth. Most tumors that enlarge on immunotherapy are genuinely progressing. The distinction matters because stopping a working treatment based on a misread scan would be a costly error, and continuing a failing one delays other options.

Oncologists manage this in a few ways. They look at the whole picture: is the patient feeling better or worse? Are blood markers moving? They often repeat imaging after a shorter interval rather than switching immediately. Specialized response criteria for immunotherapy trials were developed precisely to account for this pattern, requiring confirmation of apparent progression on a follow-up scan before declaring failure.

For patients, the practical lesson is to expect nuance from early scans. A report that says “increased size” is not automatically bad news, and a team that wants to “scan again in a few weeks” is exercising judgment, not stalling.

Complete response, no evidence of disease, remission, cure: what is the difference?

These terms get used interchangeably in conversation and mean different things on a chart.

A complete response means imaging and other tests can no longer detect measurable cancer after treatment. It is a snapshot. Microscopic disease below the resolution of a CT scan may still exist, which is why the term stops short of “gone.”

No evidence of disease, often abbreviated NED, carries the same idea from a slightly different angle: we looked with the tools we have and found nothing. It is a description of what tests show, not a biological guarantee.

Remission is the broader clinical word. Partial remission means the cancer shrank substantially. Complete remission overlaps with complete response. Both describe a state that could, in principle, end.

Cure means the cancer will not come back. Because you cannot observe a future non-event, cure is a conclusion reached in retrospect, usually after enough years pass that relapse becomes very unlikely for that cancer type. For some cancers that threshold is five years; for others, including some that relapse late, it is longer.

Immunotherapy has pushed a meaningful number of stage 4 patients into complete responses that have held for years off treatment. Those people are, in every practical sense, living as though cured. Their oncologists write “durable complete response” because the follow-up data that would let them write “cured” are still accumulating. The gap between the two phrases is time, not doubt about what the scans show.

What are the side effects of immunotherapy, and how are they different from chemotherapy?

Chemotherapy side effects come from collateral damage to healthy dividing cells: hair follicles, gut lining, bone marrow. Immunotherapy side effects come from an immune system that, once released, may not distinguish tumor from self. The National Cancer Institute calls these immune-related adverse events, and they follow a different logic.

Fatigue and skin rash are among the most common. Beyond those, almost any organ can be affected. The colon can become inflamed, causing persistent diarrhea. The lungs can develop inflammation that presents as breathlessness or dry cough. The thyroid can be knocked out of balance, sometimes permanently, leading to lifelong hormone replacement. Less often, the liver, pituitary gland, joints, heart, or nervous system are involved.

Timing is unpredictable. Chemotherapy side effects cluster in the days after each dose. Immune-related events can appear weeks or even months into treatment, and occasionally after it ends. Many are mild and manageable; some are serious and need prompt attention.

The paradox patients often hear about is real: developing certain immune side effects has been associated in some studies with a higher likelihood of the tumor responding, presumably because both reflect an activated immune system. That association is not strong enough to wish for side effects, and the absence of side effects does not mean treatment is failing.

Management typically involves pausing treatment and, when needed, medicines that calm the immune response, decisions that belong to the prescribing team. What patients can control is reporting. New symptoms, however minor they seem, deserve a call rather than a wait.

How long do people stay on immunotherapy, and can you stop?

This is one of the liveliest debates in the field, and the honest answer is that the optimal duration is not settled.

Chemotherapy has a natural stopping logic: cumulative toxicity limits how long you can give it. Immunotherapy does not exhaust the body in the same way, so in principle it could continue indefinitely. Many large trials chose a fixed treatment period, after which patients stopped and were monitored. Follow-up from those trials, as summarized in the Ribas and Wolchok review, showed that a meaningful share of responders kept responding after treatment ended, consistent with immune memory doing the work.

Other patients continue treatment as long as it helps and is tolerated. Some stop early because of side effects and, encouragingly, often maintain their response anyway. A few stop, relapse, and are treated again, sometimes successfully.

The decision weighs several things: how complete the response is, how long it has held, what side effects have appeared, and the patient’s own priorities. Someone with a complete response after two years and a demanding job may reasonably choose to stop and watch. Someone with a partial response and no side effects may prefer to continue.

There is no universal right answer yet, and any specific plan belongs to the oncologist who knows the full picture. What the science supports is a genuine conversation rather than a fixed rule, which is itself a change from how stage 4 cancer used to be managed.

Beyond checkpoint inhibitors: CAR T-cells, vaccines, and combination therapy

Checkpoint inhibitors dominate the conversation because they were first and work across many cancers, but they are one branch of a wider tree.

CAR T-cell therapy takes a more engineered approach. A patient’s T cells are collected, modified to carry a receptor that locks onto a specific protein on the cancer, expanded, and infused back. The National Cancer Institute describes approved uses in certain blood cancers, where results in patients who had run out of options have been striking, including long remissions. Solid tumors have proven harder, because finding a target present on cancer cells and absent from vital tissues is difficult, and because solid tumors defend themselves more effectively. The treatment also carries its own distinctive risks, including a systemic inflammatory reaction that requires hospital-level monitoring.

Cancer vaccines aim to teach rather than release. Rather than preventing infection, therapeutic vaccines present tumor proteins to the immune system to provoke a response. Personalized versions built around an individual’s tumor mutations are in trials.

Combinations are where much current effort sits. Pairing two checkpoint inhibitors that act at different points raised response rates in melanoma compared with either alone, at the cost of more side effects. Pairing immunotherapy with chemotherapy, radiation, or targeted drugs is standard in some cancers, on the theory that killing tumor cells releases proteins that help the immune system learn.

None of these has changed the fundamental answer to the headline question. They have widened the group of people for whom a durable response is possible, which is the direction the field is trying to move.

Questions worth asking your oncology team about immunotherapy

A good consultation about immunotherapy is a two-way exchange, and most oncologists welcome specific questions. These are the ones that tend to change the conversation.

• Has my tumor been tested for markers that predict immunotherapy response, and what did they show?
• In people with my cancer type and markers, roughly what fraction respond, and what fraction have long-lasting responses?
• What is the goal here: shrinking the cancer, controlling it, or aiming for a long remission?
• How and when will we know whether it is working, and how will you handle a scan that looks worse early on?
• Which side effects should prompt an immediate call, and who do I call after hours?
• If this works, how long would I stay on it, and what would make you recommend stopping?
• Is there a clinical trial I should consider, and how would it compare with standard treatment?

Bring someone with you if you can. Immunotherapy conversations involve probabilities, timelines, and unfamiliar vocabulary, and two sets of ears catch more. Ask for the numbers written down. If a figure is quoted, ask whether it comes from patients like you or from a broader group.

One more question is worth asking yourself rather than your doctor: what does a good outcome look like to you? For some people it is maximum time at any cost. For others it is time that feels like their own. Immunotherapy, with its potential for long treatment-free stretches, has made that second answer more achievable than it used to be, and your team can plan better if they know which one you mean.

When to seek care during immunotherapy: red-flag symptoms

Because immune-related side effects can involve any organ and can appear at any point, including after treatment ends, patients on immunotherapy should have a low threshold for contacting their team. Call your oncology unit the same day, or seek emergency care if the unit is closed, for any of the following.

Persistent diarrhea, especially with blood, mucus, or abdominal pain, can signal colitis, which the National Cancer Institute lists among the recognized immune-related effects. New or worsening shortness of breath, chest pain, or a dry cough that will not settle may indicate lung inflammation and should never be waited out. Severe headache, vision changes, or sudden confusion can point to inflammation of the pituitary or nervous system. A rash that spreads rapidly, blisters, or involves the mouth or eyes needs urgent assessment. Yellowing of the skin or eyes, dark urine, or pain under the right ribs may reflect liver involvement. Fever is always a call; it can mean infection in someone whose immune system is behaving unusually.

Extreme fatigue, unexplained weight change, feeling unusually cold or hot, or a racing heart can be thyroid or hormone disturbances that are very treatable when caught.

Do not adjust or skip treatment on your own, and do not assume a symptom is “just the cancer.” Immune-related effects are far easier to manage early, and prompt attention is one of the few parts of this process a patient can directly control.

Frequently asked questions

Can immunotherapy cure stage 4 cancer?

Not reliably, but for some patients with certain cancers it has produced remissions lasting many years, which earlier treatments almost never did. Oncologists describe these as durable responses rather than cures because follow-up is still maturing. Melanoma has the strongest evidence; many other metastatic cancers respond less often or not at all. Your individual odds depend on cancer type and tumor markers, so they are a conversation for your oncology team.

What is a durable response in immunotherapy?

A durable response is tumor shrinkage or disappearance that holds for a prolonged period, often defined as a year or more, and in the best cases for many years after treatment ends. It reflects what has been observed rather than a prediction of permanence. The term is used because immunotherapy survival curves in cancers like melanoma often flatten into a plateau, suggesting the immune system continues controlling the cancer on its own.

What percentage of stage 4 patients respond to immunotherapy?

It varies enormously by cancer type and biomarkers, so no single figure applies. In metastatic melanoma, long-term follow-up of early checkpoint trials summarized in a 2018 Science review showed roughly one in five patients alive many years later. In cancers such as pancreatic or most prostate cancers, checkpoint inhibitors have shown little benefit so far. Ask your oncologist for figures specific to your cancer and its markers.

How long does immunotherapy take to work?

Usually longer than chemotherapy, because the treatment has to activate and expand immune cells rather than kill tumor cells directly. The National Cancer Institute notes that immunotherapy can take longer to show an effect on scans. Most teams schedule a first imaging check a couple of months in. Some patients feel better before scans change, while others notice nothing until a good report arrives.

Why does my tumor look bigger on my first scan after starting immunotherapy?

It may be true progression, which is the more common explanation, or it may be pseudoprogression, where immune cells flooding into the tumor make it measure larger without the cancer actually growing. Oncologists distinguish the two by considering symptoms, blood markers, and a repeat scan after a shorter interval. Response criteria for immunotherapy trials require confirming apparent growth before declaring treatment failure.

Can stage 4 cancer go into remission with immunotherapy?

Yes, for a subset of patients. Some people with metastatic disease achieve a complete response, meaning no measurable cancer on imaging, and a portion of those responses have held for years off treatment. This is best documented in melanoma and certain other cancers. Remission is not the same as cure, and most stage 4 patients do not reach complete remission, but the possibility is real in a way it was not a generation ago.

Does immunotherapy work for all types of cancer?

No. Checkpoint inhibitors have established benefit in melanoma, non-small cell lung cancer, kidney and bladder cancers, certain lymphomas, and any tumor with a mismatch-repair defect. They have shown limited benefit so far in pancreatic cancer and most breast, prostate, and colorectal cancers, which tend to have fewer mutations and an immune-cold environment. Research on making cold tumors responsive is active but not yet standard care.

What are the most serious side effects of immunotherapy?

Immune-related inflammation of the colon, lungs, liver, hormone glands, heart, or nervous system. Fatigue and rash are more common and usually mild, but colitis with persistent diarrhea, pneumonitis with breathlessness, and hormone disturbances can be serious and sometimes permanent. These effects can appear at any point, including after treatment ends. Early reporting makes them far easier to manage, so new symptoms warrant a same-day call.

Can you stop immunotherapy if the cancer is gone?

Sometimes, and it is an active area of discussion. Many trials treated for a fixed period and then monitored patients, and a meaningful share of responders maintained their response afterward, consistent with immune memory. Others continue as long as treatment helps and is tolerated. The decision depends on how complete and how long-lasting the response is, side effects, and personal priorities, and it rests with the treating oncologist.

Is having side effects a sign that immunotherapy is working?

Some studies have found an association between developing certain immune-related side effects and a higher chance of tumor response, likely because both reflect an activated immune system. The link is not strong enough to rely on. Many people respond well with minimal side effects, and having side effects does not guarantee benefit. Scans, symptoms, and blood tests remain the way your team judges whether treatment is working.

This article is for general information only and is not a substitute for professional medical advice. Please consult a qualified doctor about your individual situation.